Navigation Links
Hospira Receives TGA Approval for Nivestim™, Australia's First Biosimilar Filgrastim

MELBOURNE, Australia, Sept. 26 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that it has received Australian Therapeutic Goods Administration (TGA) approval for its biosimilar filgrastim product, Nivestim™.

Nivestim has been approved for a range of indications, including the prevention of febrile neutropenia (FN) and reduction in duration of chemotherapy-induced neutropenia (CIN). Neutropenia is the most serious hematological toxicity that occurs as a result of cancer chemotherapy and can lead to chemotherapy dose reductions and/or dose delays compared with the prescribed schedule.(1)

Nivestim is the first biosimilar version of Neupogen® approved in Australia. Neupogen has current sales within Australia of approximately AUD25 million (U.S. $24 million). Hospira is working closely with Australian government agencies to ensure efficient market access for biosimilars, and has submitted an application to have Nivestim listed on the Australian Pharmaceutical Benefits Scheme. Listing and product launch are expected during the first half of 2011.

"Approval of Nivestim, the first biosimilar filgrastim in Australia, is another important milestone for Hospira as we build our global biosimilars portfolio," said Tim Oldham, president, Asia Pacific, Hospira. "Nivestim will help reduce the cost of providing this lifesaving therapy across Australia, and includes a unique combination of administration, storage and safety features that will enhance safety for healthcare professionals and patients."

Three pre-filled syringe presentations of Nivestim were approved in Australia: 300 mcg/0.5 mL, 480 mcg/0.5 mL and a unique 120 mcg/0.2 mL low body weight presentation.

In a large, randomized Phase lll study, Nivestim demonstrated comparable efficacy to Neupogen in the prevention of FN, and was as well tolerated, with a similar adverse event profile.(2)

Nivestim is Hospira's second biosimilar and first in Australia. The company's biosimilar erythropoietin, Retacrit™, is currently available in 17 European countries, and Nivestim was approved by the European Commission in June 2010.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 13,500 employees. The head office for Hospira in the Asia Pacific region is in Melbourne, Australia. Learn more at

Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Hospira's goals with respect to Nivestim. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, legal, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission and subsequently filed Quarterly Reports on Form 10-Q, which are  incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.

(1) Crawford J, Dale DC, Lyman GH. Chemotherapy-Induced Neutropenia: Risks, Consequences, and New Directions for Its Management. Cancer, 2004; 100(2): 228-37

(2) Waller, CF et al. Biosimilar filgrastim is an effective primary prophylactic therapy for neutropenia in patients (pts) receiving doxorubicin and docetaxel (AT) for breast cancer (BC). Poster presentation at the joint ECCO 15 and 34th ESMO Multidisciplinary Congress: Abstract E15-1238, 2009.

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Japan Receives Approval for New Indication for Precedex IV™ 200ug
2. Hospira Announces CEO Succession Plan
3. Hospira to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference Aug. 12
4. Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
5. Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections
6. Hospira Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
7. Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.)
8. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
9. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
10. Hospira Highlights a Year of Significant Progress at Its 2010 Annual Meeting of Shareholders
11. Hospira to Present at Citi 2010 Global Health Care Conference May 27, 2010
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... combineert immunotherapie met Bremachlorin-photodynamische therapie voor de ... ) --> ... ) Uit een ... (LUMC) blijkt dat ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare ... participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was ... November 8th through Wednesday, November 11th, 2015. The conference was held at the ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... has collaborated with Women’s Web – an online resource for Indian women ... mental and emotional well-being relationship, life balance, stress, professional development, and lifestyle. ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... more aggressive than those found on mammography, according to a study published online ... additional cancers not seen on mammography may necessitate a change in treatment. , ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season ... and pleasing the palates of attendees is of the utmost importance. Whether you ... seasonal get-together, give these recipes a try this holiday season. , Turkey Croquettes ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one ... for its stellar workplace culture with the company’s Cincinnati office being named a ... Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual Greater ...
Breaking Medicine News(10 mins):